GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...

Plus, there’s extensive evidence that many people who take GLP-1s do not in fact have an easy time taking the drugs. There ...

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonists reduced mortality vs. DDP-4 ...

SAN DIEGO — Patients with obesity and diabetes are at a substantially reduced risk of having a recurrence of atrial fibrillation (AF) after ablation if they are taking a glucagon-like peptide 1 (GLP-1 ...

CHICAGO -- In patients with type 2 diabetes and obesity, use of GLP-1 receptor agonists was associated with a lower risk of obesity-related cancers and death from any cause, a target trial emulation ...

People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems.

Discover a study comparing tirzepatide, semaglutide, and liraglutide in MASLD, revealing significant reductions in liver ...

Patients with lupus and type 2 diabetes are predisposed to a disproportionate risk of atherosclerotic cardiovascular disease and chronic kidney disease. A study of this patient population showed that ...

Although the use of glucagon-like peptide 1 (GLP-1) receptor agonists and other antidiabetic medications continues to increase among pregnant women with type 2 diabetes, current evidence suggests no ...